Supporting discoveries since 1987


At least two "valleys of death" have been identified in the spectrum of biomedical research where blockage occurs in translating advances in scientific knowledge to clinical practice and decision making1. One "valley" is the translation of basic scientific knowledge to create new diagnostic techniques or therapeutic interventions that can be used in the care of patients. The analysis of human biospecimens can help cross these barriers. The analysis of biospecimens are used to either confirm the biochemical/biophysical/genetic mechanisms of disease or to test biospecimens in the workup of new diagnostic procedures or confirmation of biological outcomes of therapeutic interventions. It is the difficulty and expense in obtaining appropriate groups of human biospecimens to do such studies that contribute greatly to the obstacles in advancing biomedical research.

tissue microarrayTMApancreatic cancercancer researchKDM6A

The CHTN mission is to provide prospectively procured biospecimens to scientific investigators with the ability to modify procurement and specimen processing procedures to suit the individual protocol of each investigator. Basic demographic information and clinicopathologic data abstracted from pathology reports are provided to investigators. More detailed clinical annotation may be obtained by arrangement.

Most tissue specimens procured by the CHTN are distributed to investigators as fresh/viable aliquots or snap-frozen. Quality control (QC) for all tissue samples consists of histologic analysis of a paired formalin-fixed paraffin-embedded (FFPE) tissue segment that is examined by a board-certified anatomic pathologist ensuring the delivery of correct tissue type and the elimination of highly necrotic specimens (Fig. A).

For tumor specimens, tumor cellularity, percent stroma and percent necrosis are also recorded (Fig. B). The histologic QC procedures created by the... Read more

biospecimenscancer researchquality assurancehistologyhistologic QCtumor cellularity

The CHTN takes note that human tissue samples continue to play a major role in cancer research. One of the latest national cancer research efforts takes the form of the so called “Cancer Moonshot” program that has been organized by the office of Vice-President Joe Biden. While the CHTN itself has not been tapped for this effort, some of the CHTN Principal Investigators have been involved in information-gathering and organizational efforts for this program. One subprogram of the Cancer Moonshot has been thematically termed the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) consortium. APOLLO will build on the enormously successful The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC). These previous programs have provided open access to raw genomic and proteomic data to cancer researchers that have been useful in both discovery research by data mining and validation of laboratory molecular findings in a larger dataset. Some... Read more

cancer researchMoonshot for CancerNCICHTNAPOLLO